Aluminum contamination of neonatal parenteral nutrient solutions and additives.
Aluminum contamination of neonatal parenteral nutrient solutions and additives.
复制标题
新生儿肠外营养液和添加剂的铝污染。
DOI:
10.1093/ajhp/55.10.1071
复制
发表时间:
1998
期刊:
影响因子:
--
通讯作者:
V. Herson
中科院分区:
文献类型:
--
作者:
J. F. Mouser;A. Wu;V. Herson
roglitazone has been found not to interact clinically with or alter the pharmacokinetics of acetaminophen, sulfonylureas, digoxin, or warfarin. 1 However, bile acid sequestrants such as cholestyramine may decrease the absorption of troglitazone by about 70%. Troglitazone has been found to decrease the plasma concentrations of oral contraceptives and terfenadine by 30% and 50–70%, respectively, presumably by competing with the cytochrome P-450 3A4 metabolic pathway. Also, approximately 99% of circulating troglitazone is bound to plasma proteins and thus may displace other drugs from the proteins. 1 There have been no published reports of an interaction between troglitazone and warfarin. This letter describes troglitazone apparently potentiating the effect of warfarin on the International Normalized Ratio (INR). A 51-year-old man was admitted to the hospital in August 1997 for repeat femoral–popliteal arterial bypass grafting; the procedure had first been performed in January 1997. He had received a mechanical aortic valve in 1979 and was taking warfarin to prevent thromboembolism. During the previous seven months, his INR had been stable at between 2.4 and 3.3 (goal, 2.5–3.5), and the weekly total of his daily warfarin sodium doses had been 45 mg. He had a history of severe peripheral vascular disease (with a transient ischemic attack), diabetes mellitus, hypertension, and depression.